Skip to main content
Premium Trial:

Request an Annual Quote

Wako to be Biocius' Japan Distributor

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Biocius Life Sciences said that it has signed up Wako Pure Chemical Industries to distribute its mass spectrometry systems and services in Japan, under an agreement announced today.

Osaka-based Wako will be the exclusive distributor in Japan for the Biocius RapidFire label-free high-throughput systems and for the firm's portfolio of contract research offerings and services, including in vitro ADME screening applications, such as the recently launched RF300 system, Biocius said.

Wako's BioMedical Systems Department GM Haruki Oishi said in a statement that Biocius' tools and services "will enable us to provide our customers with drug discovery solutions" and with "a means to investigate therapeutics that have been difficult to analyze by conventional methods."

Wako will support the Biocius technology in Japan with application scientists and field support engineers.

Biocius was spun out of BioTrove late last year, following that firm's acquisition by Life Technologies.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.